External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul><li>Clarity have announced further positive data from their ongoing Phase I/IIa theranostic trial in mCRPC with 64Cu-/67Cu-SAR-bisPSMA.</li><li>Dosing of the therapeutic agent (67Cu) at the highest dose of 12GBq has now been completed with no dose-limiting toxicities in Cohort 3 (n=6) allowing Clarity to progress straight into Cohort 4 with a multi-dose of 12+12GBq (2 cycles).</li><li>The impressive initial responses following a single dose of the Tx agent have continued, in this case in high pre-treated patients (5.5 median lines of prior therapy) with impressive PSA declines (27% of patients &gt;80% decline post a single dose). </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Clarity have announced further positive data from their ongoing Phase I/IIa theranostic trial in mCRPC with 64Cu-/67Cu-SAR-bisPSMA.Dosing of the therapeutic agent (67Cu) at the highest dose of 12GBq has now been completed with no dose-limiting toxicities in Cohort 3 (n=6) allowing Clarity to progress straight into Cohort 4 with a multi-dose of 12+12GBq (2 cycles).The impressive initial responses following a single dose of the Tx agent have continued, in this case in high pre-treated patients (5.5 median lines of prior therapy) with impressive PSA declines (27% of patients &gt;80% decline post a single dose). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - More Positive Data SECuREd